Across all types of included cancers and study designs, a significant improvement on OS amongst G-CSF-treated patients compared to those with placebo/no prophylaxis were found (HR 0.72, 95% CI: 0.56–0.91, I2: 54%, Figure 2A). The gene discussed is CSF3; the disease is cancer.